Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
5.82
-0.01 (-0.17%)
Mar 14, 2025, 11:14 AM EDT - Market open
Kezar Life Sciences Employees
Kezar Life Sciences had 58 employees as of December 31, 2023. The number of employees decreased by 26 or -30.95% compared to the previous year.
Employees
58
Change (1Y)
-26
Growth (1Y)
-30.95%
Revenue / Employee
n/a
Profits / Employee
-$1,651,345
Market Cap
42.46M
Employees Chart
KZR News
- 23 days ago - Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025 - Business Wire
- 4 months ago - Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 4 months ago - Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR) - Business Wire
- 4 months ago - Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - Business Wire
- 5 months ago - Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan - Business Wire
- 5 months ago - Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update - Business Wire
- 5 months ago - Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal - Business Wire
- 5 months ago - US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial - Reuters